Humoral immunity to HIV-1: Neutralization and beyond

Journal of Internal Medicine

Volumn 262, Issue 1, 2007, Pages 5-25

  Huber, M ^a   Trkola, A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Antibody dependent cellular cytotoxicity; Complement; Human immunodeficiency virus type 1; Humoral immunity; Neutralizing antibodies

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT GLYCOPROTEIN GP 120; VIRUS ENVELOPE PROTEIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT SYSTEM; CONFERENCE PAPER; CONFORMATIONAL TRANSITION; CYTOTOXICITY TEST; DOWN REGULATION; DRUG ACTIVITY; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; EFFECTOR CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IN VIVO STUDY; MOLECULAR INTERACTION; PHAGOCYTOSIS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; VIRION; VIRUS NEUTRALIZATION;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; COMPLEMENT ACTIVATION; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; PHAGOCYTOSIS;

EID: 34347214119     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2007.01819.x     Document Type: Conference Paper

References (271)

1. Groopman JE. Laying the groundwork for neutralizing AIDS-linked virus. Nature 1985 316 : 12.
2. Robert-Guroff M, Brown M, Gallo RC. HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature 1985 316 : 72 4.
3. Weiss RA, Clapham PR, Cheingsong-Popov R et al. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature 1985 316 : 69 72.
4. Belec L, Dupre T, Prazuck T et al. Cervicovaginal overproduction of specific IgG to human immunodeficiency virus (HIV) contrasts with normal or impaired IgA local response in HIV infection. J Infect Dis 1995 172 : 691 7.
5. Binley JM, Klasse PJ, Cao Y et al. Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J Virol 1997 71 : 2799 809.
6. Pellegrin I, Legrand E, Neau D et al. Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads. J Acquir Immune Defic Syndr Hum Retrovirol 1996 11 : 438 47.
7. Pilgrim AK, Pantaleo G, Cohen OJ et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 1997 176 : 924 32.
8. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003 100 : 4144 9.
9. Aasa-Chapman MM, Hayman A, Newton P et al. Development of the antibody response in acute HIV-1 infection. AIDS 2004 18 : 371 81.
10. Pincus SH, Messer KG, Nara PL, Blattner WA, Colclough G, Reitz M. Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers. J Clin Invest 1994 93 : 2505 13.
11. Parren PW, Moore JP, Burton DR, Sattentau QJ. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS 1999 13 (Suppl. A S137 62.
12. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998 280 : 1884 8.
13. Logvinoff C, Major ME, Oldach D et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A 2004 101 : 10149 54.
14. Hangartner L, Zellweger RM, Giobbi M et al. Nonneutralizing antibodies binding to the surface glycoprotein of lymphocytic choriomeningitis virus reduce early virus spread. J Exp Med 2006 203 : 2033 42.
15. Patrick Sissons JG, Schreiber RD, Perrin LH, Cooper NR, Muller-Eberhard HJ, Oldstone MB. Lysis of measles virus-infected cells by the purified cytolytic alternative complement pathway and antibody. J Exp Med 1979 150 : 445 54.
16. Blue CE, Spiller OB, Blackbourn DJ. The relevance of complement to virus biology. Virology 2004 319 : 176 84.
17. Reading PC, Hartley CA, Ezekowitz RAB, Anders EM. A serum mannose-binding lectin mediates complement-dependent lysis of influenza virus-infected cells. Biochem Biophys Res Commun 1995 217 : 1128.
18. Sinclair AL, Habeshaw JA, Muir L et al. Antibody-dependent cell-mediated cytotoxicity: comparison between HTLV- I and HIV-1 assays. AIDS 1988 2 : 465 72.
19. Kohl S, Strynadka NC, Hodges RS, Pereira L. Analysis of the role of antibody-dependent cellular cytotoxic antibody activity in murine neonatal herpes simplex virus infection with antibodies to synthetic peptides of glycoprotein D and monoclonal antibodies to glycoprotein B. J Clin Invest 1990 86 : 273 8.
20. Kohl S, West MS, Prober CG, Sullender WM, Loo LS, Arvin AM. Neonatal antibody-dependent cellular cytotoxic antibody levels are associated with the clinical presentation of neonatal herpes simplex virus infection. J Infect Dis 1989 160 : 770 6.
21. Patel PC, Menezes J. Epstein-Barr virus (EBV)-lymphoid cell interactions: II. The influence of the EBV replication cycle on natural killing and antibody-dependent cellular cytotoxicity against EBV-infected cells. Clin Exp Immunol 1982 48 : 589 601.
22. Chan SH, Levine PH, de The GB et al. A comparison of the prognostic value of antibody-dependent lymphocyte cytotoxicity and other EBV antibody assays in Chinese patients with nasopharyngeal carcinoma. Int J Cancer 1979 23 : 181 5.
23. Klasse PJ, Sattentau QJ. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J Gen Virol 2002 83 : 2091 108.
24. Fujinami RS, Oldstone MB. Antiviral antibody reacting on the plasma membrane alters measles virus expression inside the cell. Nature 1979 279 : 529 30.
25. Levine B, Hardwick JM, Trapp BD, Crawford TO, Bollinger RC, Griffin DE. Antibody-mediated clearance of alphavirus infection from neurons. Science 1991 254 : 856 60.
26. Pincus SH, Cole R, Ireland R, McAtee F, Fujisawa R, Portis J. Protective efficacy of nonneutralizing monoclonal antibodies in acute infection with murine leukemia virus. J Virol 1995 69 : 7152 8.
27. Dimmock NJ. Neutralization of animal viruses. Curr Top Microbiol Immunol 1993 183 : 1 149.
28. Dowdle WR, Downie JC, Laver WG. Inhibition of virus release by antibodies to surface antigens of influenza viruses. J Virol 1974 13 : 269 75.
29. Rodriguez JE, Moninger T, Grose C. Entry and egress of varicella virus blocked by same anti-gH monoclonal antibody. Virology 1993 196 : 840.
30. Shariff DM, Hallworth J, Desperbasques M, Buchan A, Skinner GR. Immune inhibition of virus release from herpes simplex virus-infected cells by human sera. Intervirology 1988 29 : 125 32.
31. Sairenji T, Reisert PS, Spiro RC, Connolly T, Humphreys RE. Inhibition of Epstein-Barr virus (EBV) release from the P3HR-1 Burkitt's lymphoma cell line by a monoclonal antibody against a 200,000 dalton EBV membrane antigen. J Exp Med 1985 161 : 1097 111.
32. Pierson TC, Doms RW. HIV-1 entry and its inhibition. Curr Top Microbiol Immunol 2003 281 : 1 27.
33. Parren PW, Burton DR. The antiviral activity of antibodies in vitro and in vivo. Adv Immunol 2001 77 : 195 262.
34. Xiang S-H, Doka N, Choudhary RK, Sodroski J, Robinson JE. Characterization of CD4-induced epitopes on the HIV Type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS Res Hum Retroviruses 2002 18 : 1207 17.
35. Decker JM, Bibollet-Ruche F, Wei X et al. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 2005 201 : 1407 19.
36. Trkola A, Dragic T, Arthos J et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996 384 : 184 7.
37. Wu L, Gerard NP, Wyatt R et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996 384 : 179 83.
38. Pantophlet R, Burton DR. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 2006 24 : 739 69.
39. Jolly C, Kashefi K, Hollinshead M, Sattentau QJ. HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med 2004 199 : 283 93.
40. Jolly C, Sattentau QJ. Retroviral spread by induction of virological synapses. Traffic 2004 5 : 643 50.
41. McDonald D, Wu L, Bohks SM, KewalRamani VN, Unutmaz D, Hope TJ. Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 2003 300 : 1295 7.
42. Arrighi JF, Pion M, Garcia E et al. DC-SIGN-mediated infectious synapse formation enhances X4 HIV-1 transmission from dendritic cells to T cells. J Exp Med 2004 200 : 1279 88.
43. Sato H, Orenstein J, Dimitrov D, Martin M. Cell-to-cell spread of HIV-1 occurs within minutes and may not involve the participation of virus particles. Virology 1992 186 : 712 24.
44. Bangham CR. The immune control and cell-to-cell spread of human T-lymphotropic virus type 1. J Gen Virol 2003 84 : 3177 89.
45. Pantaleo G, Demarest JF, Vaccarezza M et al. Effect of anti-V3 antibodies on cell-free and cell-to-cell human immunodeficiency virus transmission. Eur J Immunol 1995 25 : 226 31.
46. Hooks JJ, Burns W, Hayashi K, Geis S, Notkins AL. Viral spread in the presence of neutralizing antibody: mechanisms of persistence in foamy virus infection. Infect Immun 1976 14 : 1172 8.
47. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998 393 : 648 59.
48. Zhu P, Liu J, Bess J Jr. et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 2006 441 : 847 52.
49. Sattentau QJ, Moore JP. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J Exp Med 1995 182 : 185 96.
50. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, Gregory TJ. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 1990 265 : 10373 82.
51. Parren PW, Burton DR, Sattentau QJ. HIV-1 antibody - debris or virion Nat Med 1997 3 : 366 7.
52. Fouts TR, Binley JM, Trkola A, Robinson JE, Moore JP. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J Virol 1997 71 : 2779 85.
53. Moore PL, Crooks ET, Porter L et al. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 2006 80 : 2515 28.
54. Miller MD, Geleziunas R, Bianchi E et al. A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci U S A 2005 102 : 14759 64.
55. Gorny MK, Zolla-Pazner S. Human monoclonal antibodies that neutralize HIV-1. In : Korber BTM, Brander C, Haynes BF, Koup R, Moore JP, Walker BD, Watkins DI. eds. HIV Immunology and HIV/SIV Vaccine Databases 2003. Los Alamos, N. Mex : Los Alamos National Laboratory, Theoretical Biology and Biophysics, 2003 37 51.
56. Burton DR, Stanfield RL, Wilson IA. Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci U S A 2005 102 : 14943 8.
57. Haynes BF, Montefiori DC. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev Vaccines 2006 5 : 347 63.
58. Sattentau QJ, Zolla-Pazner S, Poignard P. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology 1995 206 : 713.
59. Binley JM, Ditzel HJ, Barbas CF III. et al. Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. AIDS Res Hum Retroviruses 1996 12 : 911 24.
60. Earl PL, Broder CC, Doms RW, Moss B. Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. J Virol 1997 71 : 2674 84.
61. Muster T, Steindl F, Purtscher M et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993 67 : 6642 7.
62. Purtscher M, Trkola A, Gruber G et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1994 10 : 1651 8.
63. Stiegler G, Kunert R, Purtscher M et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001 17 : 1757 65.
64. Zwick MB, Labrijn AF, Wang M et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001 75 : 10892 905.
65. Binley JM, Wrin T, Korber B et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004 78 : 13232 52.
66. Hovanessian AG, Briand JP, Said EA et al. The caveolin-1 binding domain of HIV-1 glycoprotein gp41 is an efficient B cell epitope vaccine candidate against virus infection. Immunity 2004 21 : 617 27.
67. Gorny MK, Xu JY, Karwowska S, Buchbinder A, Zolla-Pazner S. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol 1993 150 : 635 43.
68. Burton DR, Pyati J, Koduri R et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994 266 : 1024 7.
69. Parker CE, Deterding LJ, Hager-Braun C et al. Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. J Virol 2001 75 : 10906 11.
70. Trkola A, Purtscher M, Muster T et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996 70 : 1100 8.
71. Sanders RW, Venturi M, Schiffner L et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 2002 76 : 7293 305.
72. Calarese DA, Scanlan CN, Zwick MB et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003 300 : 2065 71.
73. de Rosny E, Vassell R, Jiang S, Kunert R, Weiss CD. Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. J Virol 2004 78 : 2627 31.
74. Cardoso RMF, Zwick MB, Stanfield RL et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 2005 22 : 163.
75. Trkola A, Pomales AB, Yuan H et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995 69 : 6609 17.
76. Saphire EO, Parren PW, Pantophlet R et al. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 2001 293 : 1155 9.
77. Scanlan CN, Pantophlet R, Wormald MR et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1->2 mannose residues on the outer face of gp120. J Virol 2002 76 : 7306 21.
78. Scanlan CN, Pantophlet R, Wormald MR et al. The carbohydrate epitope of the neutralizing anti-HIV-1 antibody 2G12. Adv Exp Med Biol 2003 535 : 205 18.
79. Ofek G, Tang M, Sambor A et al. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 2004 78 : 10724 37.
80. Yuste E, Sanford HB, Carmody J et al. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. J Virol 2006 80 : 3030 41.
81. Decker JM, Bibollet-Ruche F, Li H et al. Failure of the HIV-1 membrane proximal external region (MPER) of HIV-1 gp41 to elicit 4E10 or 2F5-like neutralizing antibodies in natural human infection. Keystone Symposia, HIV Vaccines, Keystone CO, Silverthorne, 2006.
82. Douek DC, Kwong PD, Nabel GJ. The rational design of an AIDS vaccine. Cell 2006 124 : 677.
83. Burton DR, Desrosiers RC, Doms RW et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004 5 : 233 6.
84. Moog C, Fleury HJ, Pellegrin I, Kirn A, Aubertin AM. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol 1997 71 : 3734 41.
85. Moore JP, Cao Y, Ho DD, Koup RA. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol 1994 68 : 5142 55.
86. Ferrantelli F, Ruprecht RM. Neutralizing antibodies against HIV - back in the major leagues Curr Opin Immunol 2002 14 : 495 502.
87. Bures R, Morris L, Williamson C et al. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol 2002 76 : 2233 44.
88. Frost SDW, Wrin T, Smith DM et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A 2005 102 : 18514 9.
89. Wei X, Decker JM, Wang S et al. Antibody neutralization and escape by HIV-1. Nature 2003 422 : 307 12.
90. Montefiori DC, Hill TS, Vo HTT, Walker BD, Rosenberg ES. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J Virol 2001 75 : 10200 7.
91. Montefiori DC, Pantaleo G, Fink LM et al. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis 1996 173 : 60 7.
92. Harrer T, Harrer E, Kalams SA et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses 1996 12 : 585 92.
93. Deeks SG, Schweighardt B, Wrin T et al. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J Virol 2006 80 : 6155 64.
94. Bailey JR, Lassen KG, Yang HC et al. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol 2006 80 : 4758 70.
95. Bradney AP, Scheer S, Crawford JM, Buchbinder SP, Montefiori DC. Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors. J Infect Dis 1999 179 : 1264 7.
96. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995 69 : 5087 94.
97. Wyatt R, Kwong PD, Desjardins E et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998 393 : 705 11.
98. Kwong PD, Doyle ML, Casper DJ et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002 420 : 678 82.
99. Labrijn AF, Poignard P, Raja A et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 2003 77 : 10557 65.
100. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 2004 4 : 199 210.
101. Johnson WE, Desrosiers RC. Viral persistance: HIV's strategies of immune system evasion. Annu Rev Med 2002 53 : 499 518.
102. Goulder PJR, Watkins DI. HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol 2004 4 : 630.
103. Albert J, Abrahamsson B, Nagy K et al. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 1990 4 : 107 12.
104. Geffin R, Hutto C, Andrew C, Scott GB. A longitudinal assessment of autologous neutralizing antibodies in children perinatally infected with human immunodeficiency virus type 1. Virology 2003 310 : 207 15.
105. Connick E, Marr DG, Zhang XQ et al. HIV-specific cellular and humoral immune responses in primary HIV infection. AIDS Res Hum Retroviruses 1996 12 : 1129 40.
106. Weiss RA, Clapham PR, Weber JN, Dalgleish AG, Lasky LA, Berman PW. Variable and conserved neutralization antigens of human immunodeficiency virus. Nature 1986 324 : 572 5.
107. Joos B, Trkola A, Fischer M et al. Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions. J Virol 2005 79 : 9026 37.
108. Trkola A, Kuster H, Rusert P et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005 11 : 615 22.
109. Haigwood NL, Montefiori DC, Sutton WF et al. Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J Virol 2004 78 : 5983 95.
110. Mascola JR, Stiegler G, VanCott TC et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000 6 : 207 10.
111. Poignard P, Sabbe R, Picchio GR et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 1999 10 : 431 8.
112. Parren PW, Marx PA, Hessell AJ et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001 75 : 8340 7.
113. Gauduin MC, Parren PW, Weir R, Barbas CF, Burton DR, Koup RA. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med 1997 3 : 1389 93.
114. Baba TW, Liska V, Hofmann-Lehmann R et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000 6 : 200 6.
115. Ruprecht RM, Hofmann-Lehmann R, Smith-Franklin BA et al. Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies. Transfus Clin Biol 2001 8 : 350 8.
116. Hofmann-Lehmann R, Vlasak J, Rasmussen RA et al. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol 2001 75 : 7470 80.
117. Shibata R, Igarashi T, Haigwood N et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999 5 : 204 10.
118. Armbruster C, Stiegler GM, Vcelar BA et al. Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. J Antimicrob Chemother 2004 54 : 915 20.
119. Nakowitsch S, Quendler H, Fekete H, Kunert R, Katinger H, Stiegler G. HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies. AIDS 2005 19 : 1957 66.
120. Derdeyn CA, Decker JM, Bibollet-Ruche F et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004 303 : 2019 22.
121. Frost SD, Liu Y, Pond SL et al. Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol 2005 79 : 6523 7.
122. Wu X, Parast AB, Richardson BA et al. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol 2006 80 : 835 44.
123. Smith DM, Strain MC, Frost SDW et al. Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. Virology 2006 335 : 1 5.
124. McConell J, Liu Y, Kreis C et al. Broad Neutralization of HIV-1 Variants in Couples without Evidence of Systemic Superinfection Despite Exposure. 13th Conference on Retroviruses and Opportunistic Infections, Denver, 2006. Alexandria, VA: Foundation for Retrovirology and Human Health, 2006.
125. Li M, Gao F, Mascola JR et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005 79 : 10108 25.
126. Mascola JR, D'Souza P, Gilbert P et al. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 2005 79 : 10103 7.
127. Yang X, Kurteva S, Lee S, Sodroski J. Stoichiometry of antibody neutralization of human immunodeficiency virus type 1. J Virol 2005 79 : 3500 8.
128. Herrera C, Spenlehauer C, Fung MS, Burton DR, Beddows S, Moore JP. Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site. J Virol 2003 77 : 1084 91.
129. Kohl S, Charlebois ED, Sigouroudinia M et al. Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine. J Infect Dis 2000 181 : 335 9.
130. Kopf M, Abel B, Gallimore A, Carroll M, Bachmann MF. Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat Med 2002 8 : 373 8.
131. Cavacini LA, Duval M, Robinson J, Posner MR. Interactions of human antibodies, epitope exposure, antibody binding and neutralization of primary isolate HIV-1 virions. AIDS 2002 16 : 2409 17.
132. Takada A, Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol 2003 13 : 387 98.
133. Tirado SM, Yoon KJ. Antibody-dependent enhancement of virus infection and disease. Viral Immunol 2003 16 : 69 86.
134. Robinson WE Jr., Montefiori DC, Mitchell WM et al. Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees. Proc Natl Acad Sci U S A 1989 86 : 4710 4.
135. June RA, Schade SZ, Bankowski MJ et al. Complement and antibody mediate enhancement of HIV infection by increasing virus binding and provirus formation. AIDS 1991 5 : 269 74.
136. Bakker LJ, Nottet HS, de Vos NM et al. Antibodies and complement enhance binding and uptake of HIV-1 by human monocytes. AIDS 1992 6 : 35 41.
137. Moir S, Malaspina A, Li Y et al. B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells. J Exp Med 2000 192 : 637 46.
138. Stoiber H, Kacani L, Speth C, Wurzner R, Dierich MP. The supportive role of complement in HIV pathogenesis. Immunol Rev 2001 180 : 168 76.
139. Horakova E, Gasser O, Sadallah S et al. Complement mediates the binding of HIV to erythrocytes. J Immunol 2004 173 : 4236 41.
140. Montefiori DC. Role of complement and Fc receptors in the pathogenesis of HIV-1 infection. Springer Semin Immunopathol 1997 18 : 371 90.
141. Mozdzanowska K, Maiese K, Furchner M, Gerhard W. Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology 1999 254 : 138.
142. Burrer R, Haessig-Einius S, Aubertin AM, Moog C. Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41. Virology 2005 333 : 102 13.
143. Lowell GH, Smith LF, Artenstein MS, Nash GS, MacDermott RP. Antibody-dependent cell-mediated antibacterial activity of human mononuclear cells: I. K lymphocytes and monocytes are effective against meningococi in cooperation with human imune sera. J Exp Med 1979 150 : 127 37.
144. Nathan C, Brukner L, Kaplan G, Unkeless J, Cohn Z. Role of activated macrophages in antibody-dependent lysis of tumor cells. J Exp Med 1980 152 : 183 97.
145. Hashimoto G, Wright PF, Karzon DT. Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells. J Infect Dis 1983 148 : 785 94.
146. Kohl S. Role of antibody-dependent cellular cytotoxicity in defense against herpes simplex virus infections. Rev Infect Dis 1991 13 : 108 14.
147. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002 20 : 323 70.
148. Berke G. Unlocking the secrets of CTL and NK cells. Immunol Today 1995 16 : 343 6.
149. Griffiths GM. The cell biology of CTL killing. Curr Opin Immunol 1995 7 : 343 8.
150. Kagi D, Vignaux F, Ledermann B et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994 265 : 528 30.
151. Cifone MG, Ulisse S, Santoni A. Natural killer cells and nitric oxide. Int Immunopharmacol 2001 1 : 1513.
152. Trinchieri G. Natural killer cells wear different hats: effector cells of innate resistance and regulatory cells of adaptive immunity and of hematopoiesis. Semin Immunol 1995 7 : 83.
153. Blumberg RS, Paradis T, Hartshorn KL et al. Antibody-dependent cell-mediated cytotoxicity against cells infected with the human immunodeficiency virus. J Infect Dis 1987 156 : 878 84.
154. Rook AH, Lane HC, Folks T, McCoy S, Alter H, Fauci AS. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody- dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells. J Immunol 1987 138 : 1064 7.
155. Ojo-Amaize EA, Nishanian P, Keith DE Jr. et al. Antibodies to human immunodeficiency virus in human sera induce cell-mediated lysis of human immunodeficiency virus-infected cells. J Immunol 1987 139 : 2458 63.
156. Koup RA, Robinson JE, Nguyen QV et al. Antibody-dependent cell-mediated cytotoxicity directed by a human monoclonal antibody reactive with gp120 of HIV-1. AIDS 1991 5 : 1309 14.
157. Tyler DS, Stanley SD, Zolla-Pazner S et al. Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J Immunol 1990 145 : 3276 82.
158. Evans LA, Thomson-Honnebier G, Steimer K et al. Antibody-dependent cellular cytotoxicity is directed against both the gp120 and gp41 envelope proteins of HIV. AIDS 1989 3 : 273 6.
159. Posner MR, Elboim HS, Cannon T, Cavacini L, Hideshima T. Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis. AIDS Res Hum Retroviruses 1992 8 : 553 8.
160. Hezareh M, Hessell AJ, Jensen RC, van de Winkel JGJ, Parren PWHI. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J Virol 2001 75 : 12161 8.
161. Tanneau F, McChesney M, Lopez O, Sansonetti P, Montagnier L, Riviere Y. Primary cytotoxicity against the envelope glycoprotein of human immunodeficiency virus-1: evidence for antibody-dependent cellular cytotoxicity in vivo. J Infect Dis 1990 162 : 837 43.
162. Ljunggren K, Broliden PA, Morfeldt-Manson L, Jondal M, Wahren B. IgG subclass response to HIV in relation to antibody-dependent cellular cytotoxicity at different clinical stages. Clin Exp Immunol 1988 73 : 343 7.
163. Tyler DS, Stanley SD, Nastala CA et al. Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. J Immunol 1990 144 : 3375 84.
164. Ljunggren K, Moschese V, Broliden PA et al. Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers. J Infect Dis 1990 161 : 198 202.
165. Forthal DN, Landucci G, Daar ES. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol 2001 75 : 6953 61.
166. Ahmad R, Sindhu ST, Toma E et al. Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J Clin Immunol 2001 21 : 227 33.
167. Banks ND, Kinsey N, Clements J, Hildreth JE. Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. AIDS Res Hum Retroviruses 2002 18 : 1197 205.
168. Gomez-Roman VR, Patterson LJ, Venzon D et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 2005 174 : 2185 9.
169. Florese RH, Van Rompay KK, Aldrich K et al. Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J Immunol 2006 177 : 4028 36.
170. Subbramanian RA, Xu J, Toma E et al. Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS
171. Bottiger B, Ljunggren K, Karlsson A et al. Neutralizing antibodies in relation to antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus type I. Clin Exp Immunol 1988 73 : 339 42.
172. Shepp DH, Chakrabarti S, Moss B, Quinnan GV Jr., Antibody-dependent cellular cytotoxicity specific for the envelope antigens of human immunodeficiency virus. J Infect Dis 1988 157 : 1260 4.
173. Ahmad A, Menezes J. Antibody-dependent cellular cytotoxicity in HIV infections. FASEB J 1996 10 : 258 66.
174. Ljunggren K, Bottiger B, Biberfeld G, Karlson A, Fenyo EM, Jondal M. Antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus. Presence at different clinical stages. J Immunol 1987 139 : 2263 7.
175. Ahmad A, Morisset R, Thomas R, Menezes J. Evidence for a defect of antibody-dependent cellular cytotoxic (ADCC) effector function and anti-HIV gp120/41-specific ADCC-mediating antibody titres in HIV-infected individuals. J Acquir Immune Defic Syndr 1994 7 : 428 37.
176. Sawyer LA, Katzenstein DA, Hendry RM et al. Possible beneficial effects of neutralizing antibodies and antibody- dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection. AIDS Res Hum Retroviruses 1990 6 : 341 56.
177. Baum LL, Cassutt KJ, Knigge K et al. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 1996 157 : 2168 73.
178. Jenkins M, Mills J, Kohl S. Natural killer cytotoxicity and antibody-dependent cellular cytotoxicity of human immunodeficiency virus-infected cells by leukocytes from human neonates and adults. Pediatr Res 1993 33 : 469 74.
179. Broliden K, Sievers E, Tovo PA et al. Antibody-dependent cellular cytotoxicity and neutralizing activity in sera of HIV-1-infected mothers and their children. Clin Exp Immunol 1993 93 : 56 64.
180. Ohkawa S, Wilson LA, Larosa G, Javaherian K, Martin LN, Murphey-Corb M. Immune responses induced by prototype vaccines for AIDS in rhesus monkeys. AIDS Res Hum Retroviruses 1994 10 : 27 38.
181. Belo M, Yagello M, Girard M et al. Antibody-dependent cellular cytotoxicity against HIV-1 in sera of immunized chimpanzees. AIDS 1991 5 : 169 76.
182. Broliden K, Hinkula J, Tolfvenstam T, Niphuis H, Heeney J. Antibody-dependent cellular cytotoxicity to clinical isolates of HIV-1 and SIVcpz: comparison of human and chimpanzees. AIDS 1996 10 : 1199 204.
183. Ferrari G, Place CA, Ahearne PM et al. Comparison of anti-HIV-1 ADCC reactivities in infected humans and chimpanzees. J Acquir Immune Defic Syndr 1994 7 : 325 31.
184. Lyerly HK, Reed DL, Matthews TJ et al. Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC. AIDS Res Hum Retroviruses 1987 3 : 409 22.
185. Ahmad A, Yao XA, Tanner JE, Cohen E, Menezes J. Surface expression of the HIV-1 envelope proteins in env gene- transfected CD4-positive human T cell clones: characterization and killing by an antibody-dependent cellular cytotoxic mechanism. J Acquir Immune Defic Syndr 1994 7 : 789 98.
186. Hober D, Jewett A, Bonavida B. Lysis of uninfected HIV-1 gp120-coated peripheral blood-derived T lymphocytes by monocyte-mediated antibody-dependent cellular cytotoxicity. FEMS Immunol Med Microbiol 1995 10 : 83 91.
187. Jewett A, Giorgi JV, Bonavida B. Antibody-dependent cellular cytotoxicity against HIV-coated target cells by peripheral blood monocytes from HIV seropositive asymptomatic patients. J Immunol 1990 145 : 4065 71.
188. Szelc CM, Mitcheltree C, Roberts RL, Stiehm ER. Deficient polymorphonuclear cell and mononuclear cell antibody-dependent cellular cytotoxicity in pediatric and adult human immunodeficiency virus infection. J Infect Dis 1992 166 : 486 93.
189. Klasse PJ, Moore JP. Is there enough gp120 in the body fluids of HIV-1-infected individuals to have biologically significant effects Virology 2004 323 : 1 8.
190. Ljunggren K, Karlson A, Fenyo EM, Jondal M. Natural and antibody-dependent cytotoxicity in different clinical stages of human immunodeficiency virus type 1 infection. Clin Exp Immunol 1989 75 : 184 9.
191. Scott-Algara D, Paul P. NK cells and HIV infection: lessons from other viruses. Curr Mol Med 2002 2 : 757 68.
192. Eger KA, Unutmaz D. Perturbation of natural killer cell function and receptors during HIV infection. Trends Microbiol 2004 12 : 301 3.
193. Ahmad A, Menezes J. Defective killing activity against gp120/41-expressing human erythroleukaemic K562 cell line by monocytes and natural killer cells from HIV-infected individuals. AIDS 1996 10 : 143 9.
194. Brenner BG, Dascal A, Margolese RG, Wainberg MA. Natural killer cell function in patients with acquired immunodeficiency syndrome and related diseases. J Leukoc Biol 1989 46 : 75 83.
195. Ullum H, Gotzsche PC, Victor J, Dickmeiss E, Skinhoj P, Pedersen BK. Defective natural immunity: an early manifestation of human immunodeficiency virus infection. J Exp Med 1995 182 : 789 99.
196. Mavilio D, Lombardo G, Kinter A et al. Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. J Exp Med 2006 203 : 2339 50.
197. Kedzierska K, Azzam R, Ellery P, Mak J, Jaworowski A, Crowe SM. Defective phagocytosis by human monocyte/macrophages following HIV-1 infection: underlying mechanisms and modulation by adjunctive cytokine therapy. J Clin Virol 2003 26 : 247.
198. Bender BS, Davidson BL, Kline R, Brown C, Quinn TC. Role of the mononuclear phagocyte system in the immunopathogenesis of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Rev Infect Dis 1988 10 : 1142 54.
199. Monari C, Casadevall A, Pietrella D, Bistoni F, Vecchiarelli A. Neutrophils from patients with advanced human immunodeficiency virus infection have impaired complement receptor function and preserved Fcgamma receptor function. J Infect Dis 1999 180 : 1542 9.
200. Walport MJ. Complement. First of two parts. N Engl J Med 2001 344 : 1058 66.
201. Carroll M. The complement system in regulation of adaptive immunity. Nat Immunol 2004 5 : 981 5.
202. Stager S, Alexander J, Kirby AC et al. Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses. Nat Med 2003 9 : 1287 92.
203. Davies KA, Schifferli JA, Walport MJ. Complement deficiency and immune complex disease. Springer Semin Immunopathol 1994 15 : 397 416.
204. Spear GT. The complement system in HIV infection. Clin Immunol Newsl 1991 11 : 88.
205. Senaldi G, Peakman M, McManus T, Davies ET, Tee DE, Vergani D. Activation of the complement system in human immunodeficiency virus infection: relevance of the classical pathway to pathogenesis and disease severity. J Infect Dis 1990 162 : 1227 32.
206. Cohen JH, Autran B, Jouvin MH et al. Decrease of erythrocyte receptors for the C3b fragment of complement in acquired immunodeficiency syndrome. Presse Med 1988 17 : 727 30.
207. Inada Y, Lange M, McKinley GF et al. Hematologic correlates and the role of erythrocyte CR1 (C3b receptor) in the development of AIDS. AIDS Res 1986 2 : 235 47.
208. Tausk FA, McCutchan A, Spechko P, Schreiber RD, Gigli I. Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome. J Clin Invest 1986 78 : 977 82.
209. Spear GT, Takefman DM, Sullivan BL, Landay AL, Zolla-Pazner S. Complement activation by human monoclonal antibodies to human immunodeficiency virus. J Virol 1993 67 : 53 9.
210. Haurum JS, Thiel S, Jones IM, Fischer PB, Laursen SB, Jensenius JC. Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins. AIDS 1993 7 : 1307 13.
211. Ebenbichler CF, Thielens NM, Vornhagen R, Marschang P, Arlaud GJ, Dierich MP. Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J Exp Med 1991 174 : 1417 24.
212. Spear GT, Jiang HX, Sullivan BL, Gewurz H, Landay AL, Lint TF. Direct binding of complement component C1q to human immunodeficiency virus (HIV) and human T lymphotrophic virus-I (HTLV-I) coinfected cells. AIDS Res Hum Retroviruses 1991 7 : 579 85.
213. Stoiber H, Ebenbichler C, Schneider R, Janatova J, Dierich MP. Interaction of several complement proteins with gp120 and gp41, the two envelope glycoproteins of HIV-1. AIDS 1995 9 : 19 26.
214. Stoiber H, Thielens NM, Ebenbichler C, Arlaud GJ, Dierich MP. The envelope glycoprotein of HIV-1 gp120 and human complement protein C1q bind to the same peptides derived from three different regions of gp41, the transmembrane glycoprotein of HIV-1, and share antigenic homology. Eur J Immunol 1994 24 : 294 300.
215. Aasa-Chapman MM, Holuigue S, Aubin K et al. Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. J Virol 2005 79 : 2823 30.
216. Sullivan BL, Takefman DM, Spear GT. Complement can neutralize HIV-1 plasma virus by a C5-independent mechanism. Virology 1998 248 : 173 81.
217. Stoiber H, Pinter C, Siccardi AG, Clivio A, Dierich MP. Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J Exp Med 1996 183 : 307 10.
218. Lederman MM, Purvis SF, Walter EI, Carey JT, Medof ME. Heightened complement sensitivity of acquired immunodeficiency syndrome lymphocytes related to diminished expression of decay-accelerating factor. Proc Natl Acad Sci U S A 1989 86 : 4205 9.
219. Gregersen JP, Mehdi S, Baur A, Hilfenhaus J. Antibody- and complement-mediated lysis of HIV-infected cells and inhibition of viral replication. J Med Virol 1990 30 : 287 93.
220. Schmitz J, Zimmer JP, Kluxen B et al. Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59. J Clin Invest 1995 96 : 1520 6.
221. Takefman DM, Sullivan BL, Sha BE, Spear GT. Mechanisms of resistance of HIV-1 primary isolates to complement-mediated lysis. Virology 1998 246 : 370 8.
222. Spear GT, Olinger GG, Saifuddin M, Gebel HM. Human antibodies to major histocompatibility complex alloantigens mediate lysis and neutralization of HIV-1 primary isolate virions in the presence of complement. J Acquir Immune Defic Syndr 2001 26 : 103 10.
223. Spear GT, Sullivan BL, Landay AL, Lint TF. Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis. J Virol 1990 64 : 5869 73.
224. Sullivan BL, Knopoff EJ, Saifuddin M et al. Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo. J Immunol 1996 157 : 1791 8.
225. Huber M, Fischer M, Misselwitz B et al. Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection. PLoS Med 2006 3 : 441.
226. Marschang P, Gurtler L, Totsch M et al. HIV-1 and HIV-2 isolates differ in their ability to activate the complement system on the surface of infected cells. AIDS 1993 7 : 903 10.
227. Neil SJ, McKnight A, Gustafsson K, Weiss RA. HIV-1 incorporates ABO histo-blood group antigens that sensitize virions to complement-mediated inactivation. Blood 2005 105 : 4693 9.
228. Saifuddin M, Hedayati T, Atkinson JP, Holguin MH, Parker CJ, Spear GT. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J Gen Virol 1997 78 : 1907 11.
229. Marschang P, Sodroski J, Wurzner R, Dierich MP. Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur J Immunol 1995 25 : 285 90.
230. Montefiori DC, Cornell RJ, Zhou JY, Zhou JT, Hirsch VM, Johnson PR. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. Virology 1994 205 : 82 92.
231. Saifuddin M, Ghassemi M, Patki C, Parker CJ, Spear GT. Host cell components affect the sensitivity of HIV type 1 to complement-mediated virolysis. AIDS Res Hum Retroviruses 1994 10 : 829 37.
232. Saifuddin M, Parker CJ, Peeples ME et al. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med 1995 182 : 501 9.
233. Weiss L, Okada N, Haeffner-Cavaillon N et al. Decreased expression of the membrane inhibitor of complement-mediated cytolysis CD59 on T-lymphocytes of HIV-infected patients. AIDS 1992 6 : 379 85.
234. Pinter C, Siccardi AG, Longhi R, Clivio A. Direct interaction of complement factor H with the C1 domain of HIV type 1 glycoprotein 120. AIDS Res Hum Retroviruses 1995 11 : 577 88.
235. Pinter C, Siccardi AG, Lopalco L, Longhi R, Clivio A. HIV glycoprotein 41 and complement factor H interact with each other and share functional as well as antigenic homology. AIDS Res Hum Retroviruses 1995 11 : 971 80.
236. Stoiber H, Schneider R, Janatova J, Dierich MP. Human complement proteins C3b, C4b, factor H and properdin react with specific sites in gp120 and gp41, the envelope proteins of HIV-1. Immunobiology 1995 193 : 98 113.
237. Rabinovitch M. Professional and non-professional phagocytes: an introduction. Trends Cell Biol 1995 5 : 85 7.
238. Brown EJ. Complement receptors and phagocytosis. Curr Opin Immunol 1991 3 : 76 82.
239. Azzam R, Kedzierska K, Leeansyah E et al. Impaired complement-mediated phagocytosis by HIV type-1-infected human monocyte-derived macrophages involves a cAMP-dependent mechanism. AIDS Res Hum Retroviruses 2006 22 : 619 29.
240. Van Montfort T, Nabatov AA, Geijtenbeek TB, Pollakis G, Paxton WA. Efficient capture of antibody neutralized HIV-1 by cells expressing DC-SIGN and transfer to CD4+ T lymphocytes. J Immunol 2007 178 : 3177 85.
241. Sullivan NJ. Antibody-mediated enhancement of viral disease. Curr Top Microbiol Immunol 2001 260 : 145 69.
242. Robinson WE Jr., Montefiori DC, Mitchell WM. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet 1988 1 : 790 4.
243. Homsy J, Meyer M, Tateno M, Clarkson S, Levy JA. The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. Science 1989 244 : 1357 60.
244. Perno CF, Baseler MW, Broder S, Yarchoan R. Infection of monocytes by human immunodeficiency virus type 1 blocked by inhibitors of CD4-gp120 binding, even in the presence of enhancing antibodies. J Exp Med 1990 171 : 1043 56.
245. Trischmann H, Davis D, Lachmann PJ. Lymphocytotropic strains of HIV type 1 when complexed with enhancing antibodies can infect macrophages via Fc gamma RIII, independently of CD4. AIDS Res Hum Retroviruses 1995 11 : 343 52.
246. Takeda A, Tuazon CU, Ennis FA. Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 1988 242 : 580 3.
247. Laurence J, Saunders A, Early E, Salmon JE. Human immunodeficiency virus infection of monocytes: relationship to Fc-gamma receptors and antibody-dependent viral enhancement. Immunology 1990 70 : 338 43.
248. Montefiori DC, Robinson WE Jr., Hirsch VM, Modliszewski A, Mitchell WM, Johnson PR. Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques. J Virol 1990 64 : 113 9.
249. Kozlowski PA, Black KP, Shen L, Jackson S. High prevalence of serum IgA HIV-1 infection-enhancing antibodies in HIV-infected persons. Masking by IgG. J Immunol 1995 154 : 6163 73.
250. Forthal D, Landucci G, Phan T, Higa-Tanner R, Gilbert P. Fcg Receptor IIa and IIIa Polymorphisms are associated with the Risk of HIV Infection. 13th Conference on Retroviruses and Opportunistic Infections, Denver, 2006. Alexandria, VA: Foundation for Retrovirology and Human Health, 2006.
251. Takeda A, Sweet RW, Ennis FA. Two receptors are required for antibody-dependent enhancement of human immunodeficiency virus type 1 infection: CD4 and Fc gamma R. J Virol 1990 64 : 5605 10.
252. Zeira M, Byrn RA, Groopman JE. Inhibition of serum-enhanced HIV-1 infection of U937 monocytoid cells by recombinant soluble CD4 and anti-CD4 monoclonal antibody. AIDS Res Hum Retroviruses 1990 6 : 629 39.
253. Haubrich RH, Takeda A, Koff W, Smith G, Ennis FA. Studies of antibody-dependent enhancement of human immunodeficiency virus (HIV) type 1 infection mediated by Fc receptors using sera from recipients of a recombinant gp160 experimental HIV-1 vaccine. J Infect Dis 1992 165 : 545 8.
254. Holl V, Peressin M, Decoville T et al. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol 2006 80 : 6177 81.
255. Spear GT, Lurain NS, Parker CJ, Ghassemi M, Payne GH, Saifuddin M. Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses.Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). J Immunol 1995 155 : 4376 81.
256. Stoiber H, Speth C, Dierich MP. Role of complement in the control of HIV dynamics and pathogenesis. Vaccine 2003 21 (Suppl. 2 S77 82.
257. Banki Z, Kacani L, Rusert P et al. Complement dependent trapping of infectious HIV in human lymphoid tissues. AIDS 2005 19 : 481 6.
258. Bajtay Z, Speth C, Erdei A, Dierich MP. Cutting edge: productive HIV-1 infection of dendritic cells via complement receptor type 3 (CR3, CD11b/CD18). J Immunol 2004 173 : 4775 8.
259. Banki Z, Stoiber H, Dierich MP. HIV and human complement: inefficient virolysis and effective adherence. Immunol Lett 2005 97 : 209 14.
260. Stoiber H, Pruenster M, Ammann CG, Dierich MP. Complement-opsonized HIV: the free rider on its way to infection. Mol Immunol 2005 42 : 153 60.
261. Zhou J, Montefiori DC. Complement-activating antibodies in sera from infected individuals and vaccinated volunteers that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1, CD35). Virology 1996 226 : 13 21.
262. Javaherian K, Langlois AJ, LaRosa GJ et al. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 1990 250 : 1590 3.
263. Rusche JR, Javaherian K, McDanal C et al. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. PNAS 1988 85 : 3198 202.
264. Moore JP, Cao Y, Qing L et al. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 1995 69 : 101 9.
265. Posner MR, Hideshima T, Cannon T, Mukherjee M, Mayer KH, Byrn RA. An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. J Immunol 1991 146 : 4325 32.
266. Pantophlet R, Ollmann Saphire E, Poignard P, Parren PW, Wilson IA, Burton DR. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol 2003 77 : 642 58.
267. Mascola JR, Stiegler G, VanCott TC et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000 6 : 207.
268. Draenert R, Allen TM, Liu Y et al. Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus. J Exp Med 2006 203 : 529 39.
269. Yang OO, Church J, Kitchen CM et al. Genetic and stochastic influences on the interaction of human immunodeficiency virus type 1 and cytotoxic T lymphocytes in identical twins. J Virol 2005 79 : 15368 75.
270. Haynes BF, Fleming J, St Clair EW et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005 308 : 1906 8.
271. Zanetti G, Briggs JA, Grunewald K, Sattentau QJ, Fuller SD. Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ. PLoS Pathog 2006 2 : 83.